In a strategic move set to reshape the landscape of European contract research, Utrecht-based Single Cell Discoveries (SCD) has officially completed its acquisition of TATAA Biocenter. The merger brings together SCD’s expertise in discovery transcriptomics with TATAA’s globally recognized proficiency in quantitative polymerase chain reaction (qPCR), bioanalytical services, and molecular assay development.
This acquisition marks a significant consolidation of capabilities, creating a rare specialist contract research organization (CRO) capable of taking pharmaceutical targets from initial discovery through to regulatory-ready results. By pairing SCD’s research-grade innovation with TATAA’s validated workflows, the combined entity aims to streamline the development pathway for biotech and pharmaceutical clients.
Between SCD’s headquarters in The Netherlands and TATAA’s facilities in Gothenburg, Sweden, the new organization will leverage a combined workforce of approximately 50 scientists. This expanded team offers a comprehensive suite of high-tech services: SCD contributes deep expertise in single-cell sequencing, spatial transcriptomics, high-throughput RNA sequencing, and bioinformatics, while TATAA brings robust capabilities in digital PCR, proteomics, and GLP/GCLP-compliant bioanalysis.
The primary benefit for clients is the elimination of the “silo effect” in drug development. Previously, developers often faced the logistical hurdle of moving data and samples between multiple providers as a project transitioned from early-stage discovery to clinical validation. Under the new model, a target identified through single-cell sequencing can be confirmed via spatial transcriptomics or proteomics, and then seamlessly transitioned into a GLP or GCLP-validated assay—all without the project ever leaving the integrated group’s ecosystem.
“This is a natural fit,” said Mauro Muraro, CEO of SCD. “Customers kept telling us the same thing. They loved working with us on discovery, but had to go elsewhere to validate targets for a clinical program. TATAA closes that gap. As drug developers consolidate outsourcing, working with fewer partners across more of the development pathway, this is the right move.”
Sofia Adolfsson, Scientific Officer at TATAA, emphasized the scientific synergy of the merger. “SCD’s single-cell and spatial technologies generate exceptional insight, and our GLP/GCLP-compliant qPCR and assay development can now validate those findings,” she noted. “This happens without customers switching providers, protocols, or data formats partway through a program.”
The integration of these services is effective as of September 2026. While the financial terms of the acquisition have not been disclosed, industry analysts view the deal as a timely response to the increasing demand for specialized, end-to-end outsourcing solutions in the pharmaceutical sector. As companies look to expedite the transition from bench to bedside, the SCD-TATAA union offers a unified, high-precision pathway for modern drug development.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
